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ABSTRACT 
 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease primarily 
affecting peripheral joints. In this thesis work we aimed to increase the knowledge 
about proinflammatory and antigen-specific CD4+ T cell subsets involved in RA 
pathogenesis and I also investigated the effect of T cell directed therapy (abatacept) on 
CD4+ T cell subsets.  
 
Abatacept (CTLA4-Ig) is a biologic therapy that blocks T cell co-stimulation by 
interfering with the binding of CD28 to CD80/86. Treatment of abatacept leads to 
reduced TH1 and TH17 cytokine production in ACPA-positive RA patients and 
diminished frequencies of several Treg subsets. This was also confirmed by in vitro 
studies where abatacept was added in vitro to cell cultures.  
Approximately 60% of RA patients have antibodies against citrullinated proteins 
(ACPA) and their presence is associated to HLA-DRB1*04, one of the strongest genetic 
risk factors associated with RA. It is believed that T cells recognizing citrullinated 
epitopes presented by HLA-DRB1*04 alleles may drive the development of ACPA and 
disease. We have used MHC class II tetramer technology in order to identify and 
enumerate autoantigen-specific T cells in blood and synovial fluid of RA patients. 
Several citrullinated epitopes of CILP, a-enolase, fibrinogen and vimentin were 
identified. The frequency of citrulline-specific T cells was higher in the blood of RA 
patients compared to HLA-matched healthy controls and the citrulline-specific T cells 
in RA patients were of a memory TH1 phenotype. Furthermore, we enumerated and 
characterized a-enolase native and citrulline-specific T cells in blood and synovial fluid 
of HLA-DRB1*04:01 RA patients. Higher frequencies of citrullinated a-enolase 
specific T cells were present in synovial fluid compared to blood and T cells 
recognizing the citrullinated variant of a-enolase were also more often of a memory 
phenotype (i.e. had encountered their cognate antigen in vivo) than those recognizing 
the native a-enolase epitope. Some T cells showed cross-reactivity between the two 
investigated epitopes. HLA-DRB1*04:01-IE transgenic mice were used to substantiate 
our findings.  
 
Another potentially contributing T cell subset to RA pathology is an expanded T cell 
subset that lacks the co-stimulatory molecule CD28, often referred to as CD4+CD28null 
T cells, which are present in approximately 1/3 of RA patients. These are 
proinflammatory cells and their frequency in blood can be up to 50 % of all CD4+ T 
cells, but they are infrequent in synovial fluid. CD28null T cells are different than 
conventional CD4+ T cells in several aspects, but we demonstrate that even within the 
CD28null subset there are differences due to their localization. We compared cells from 
blood and synovial fluid. CD28null cells from synovial fluid expressed more CXCR3 
and CCR6 than those form the circulation and CD28null cells from synovial fluid were 
able to produce IL-17 even though they displayed a hypomethylated IFNG promoter.  
During my thesis studies, several novel HLA-DRB1*04:01 restricted citrullinated T cell 
epitopes have been identified. The auto-reactive T cells did not overlap with the 
CD28null phenotype. We have demonstrated the proof of principle that auto-reactive T 
cells can be identified by MHC class II tetramer technology in an assay not dependent 
on in vitro stimulation. 
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